OPK

OPKO Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.160
+0.010
+0.87%
After Hours: 1.170 +0.01 +0.86% 18:35 04/03 EDT
OPEN
1.200
PREV CLOSE
1.150
HIGH
1.290
LOW
1.117
VOLUME
16.76M
TURNOVER
--
52 WEEK HIGH
2.910
52 WEEK LOW
1.117
MARKET CAP
777.00M
P/E (TTM)
-2.2057
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OPK stock price target is 4.150 with a high estimate of 6.00 and a low estimate of 3.000.

EPS

OPK News

More
  • Opko Health CEO Frost Buys 500,000 @ Avg Price: $1.16
  • Benzinga · 10h ago
  • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
  • Benzinga · 11h ago
  • Opko Health Chairman Frost Buys 643,549 @$1.23/Share
  • Benzinga · 1d ago
  • The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
  • Benzinga · 2d ago

Industry

Pharmaceuticals
-0.50%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About OPK

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
More

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.